Actively Recruiting
Impact of Gonadotoxic Therapies on Fertility
Led by Michael von Wolff · Updated on 2024-06-03
7000
Participants Needed
1
Research Sites
787 weeks
Total Duration
On this page
Sponsors
M
Michael von Wolff
Lead Sponsor
U
University of Bern
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: * in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); * in males, if cancer therapies reduce sperm concentration (sperm quality).
CONDITIONS
Official Title
Impact of Gonadotoxic Therapies on Fertility
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with cancer or benign condition and scheduled for chemotherapy and/or radiotherapy of the pelvis (females) or testicles (males) and/or immunotherapy
- Willing to participate in the study
- Aged 14 to 50 years in Austria and Switzerland, aged 18 to 50 years in Germany
- Have serum hormone analysis before gonadotoxic therapy (for females)
- Have serum hormone analysis and sperm analysis before gonadotoxic therapy (for males)
You will not qualify if you...
- Missing consent to participate
- Language barrier preventing study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Women's Hospital (Inselspital)
Bern, Switzerland, 3010
Actively Recruiting
Research Team
M
Michael von Wolff, Prof. Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here